Sir, Although highly active antiretroviral treatment (HAART) in HIV-infected pregnant women has been shown to be effective in reducing mother-to-child-transmission (MTCT), some therapeutic issues remain a concern. Changes in drug pharmacokinetics (PK) in the second and third trimesters could cause reductions in plasma exposure of several antiretrovirals, 1 while for most recent compounds few data are available. Boosted darunavir is widely used in multidrug-experienced pregnant patients, but information in this setting is limited to heterogeneous case reports showing lower trough concentrations (1168-1908 ng/mL) as compared with non-pregnant patients. 2 -6 The use of inhibitory quotients (IQs) has been proposed to individualize the exposure of drugs in relation to the harboured viruses: our group showed that the darunavir weighted score genotypic IQ (ws gIQ) was the most accurate predictor of virological response in treatmentexperienced patients. 7 Therefore the use of darunavir ws gIQ could help clinicians to manage multidrug-experienced pregnant women.
We describe the case of a young woman infected with HIV and hepatitis C virus whose therapeutic history includes suboptimal adherence to several antiretrovirals and virological failures on regimens containing efavirenz, indinavir and saquinavir. HIV polymerase revealed resistance-associated mutations both in the reverse transcriptase (D67N, T69N, K70R, A98G, M184V, K103N and K219Q) and the protease (M46I, I84V and L90M) gene. After successfully receiving tenofovir/emtricitabine and darunavir/ritonavir (800/100 mg once daily) she discontinued every treatment. Two years later she agreed to reinitiate tenofovir/emtricitabine and once-daily darunavir/ritonavir: at this time she presented with 539 CD4+ T lymphocytes/mm 3 (15%, 0.27 CD8/CD4 ratio), 55500 HIV RNA copies/mL and an R5 tropic virus. Three months later (at 10 weeks of gestational age) her pregnancy test was positive and her darunavir/ritonavir dosage was increased to 600/100 mg twice daily. After a net decrease in viral load (252 copies/mL at 16 weeks and 115 copies/mL at 20 weeks) it rebounded at 28 weeks (507 and 735 copies/mL at two different controls). Raltegravir had previously been poorly tolerated due to creatine phosphokinase elevations, therefore etravirine (200 mg twice daily) and maraviroc (150 mg twice daily) were added (at 29 weeks), leading to a sustained HIV RNA decrease (178 copies/mL at 32 weeks and ,20 copies/mL at delivery, at 38 weeks). The baby, born through elective caesarean section, did not show abnormalities and received zidovudine prophylaxis for 6 weeks; at 1 and 6 months of age his HIV-1 DNA PCR test was negative and no laboratory abnormalities were noted. Lower than expected darunavir trough concentrations both in the second (two samples, 2041 and 2192 ng/mL) and third trimester (two samples, 1768 and 1719 ng/mL) were noted; self-reported adherence was .95%. Figure 1 shows the time profile of HIV RNA, darunavir trough concentrations and darunavir ws gIQ. 7 Maternal plasma and cord blood drug concentrations were measured at delivery (and 13 h after drug intake) through validated HLPC-MS and HPLC-UV (for maraviroc) methods. 8, 9 Plasma concentrations (ng/mL), cord blood concentrations (ng/mL) and cord-to-plasma ratios were: darunavir, 1399, 212 and 0.15; ritonavir, 153, 49 and 0.32; tenofovir, 47, 53 and 1.13; emtricitabine, 151, 250 and 1.66; maraviroc, 186, 69 and 0.37; and etravirine, 421, 218 and 0.51.
The expected PK changes in the third trimester affect darunavir exposure, but their clinical impact is unknown in patients harbouring multidrug-resistant viruses; furthermore, unbound plasma concentrations seem unchanged. 10 A case report suggested that a third trimester increase in darunavir/ritonavir dosage to 900/100 mg twice daily could not counterbalance this effect. 3 Our patient is the first case showing that a modified PK of darunavir could lead to virological failure in late pregnancy, and this could be reasonably attributed to a decrease in concentration below the optimal threshold in salvage therapy. Therefore the use of darunavir ws gIQ (and possible dose-tailoring according to it) could be a clinical tool in darunavir-treated pregnant patients carrying resistant viruses. A major limitation of this case report is that we did not directly measure adherence (previously suboptimal in this patient): incomplete drug intake could possibly explain the poor efficacy, although unscheduled therapeutic drug monitoring did not point to missed doses or selective non-adherence. Use of the most recently marketed drugs has thus far not been fully assessed in pregnancy: our case confirmed previous reports on the safety and PK of etravirine in late pregnancy, while it is the first to describe maraviroc use in this setting. It is noteworthy not only because of the good tolerability and lack of early effects on the newborn of maraviroc, but data on transplacental passage showed an intermediate value (a cord-to-plasma ratio of 37%), leading to cord blood levels above the in vitro (0.26 ng/mL) and in vivo IC 50 of wild-type viruses (7.65 ng/mL).
In conclusion, the management of HAART in multidrugexperienced HIV-infected pregnant women should be individualized by tailoring drug dosages according to PK modification; the safety and efficacy of the most recent compounds need to be assessed in order to rely on the full armamentarium of antiretroviral drugs.
